ACVR1B and neoplasm: To determine whether tumor cell activin receptor signaling is important in enzalutamide resistance in vivo, we generated MycCaP-Bo cells expressing doxycycline-inducible shRNA targeting Acvr1b and Acvr2a, respectively.